When exploring the landscape of advanced biochemical research tools, the abaloparatide peptide sequence stands out as a fascinating subject of study. As someone deeply interested in the structural nuances of synthetic analogs, I have spent significant time analyzing the molecular architecture of this specific peptide. Whether you are researching its struc TYMLOS (abaloparatide) injection Label - accessdata.fda.gov tural properties or comparing it to other PTHrP-derived chains, understanding the fundamental amino acid arrangement is essential.
Structural Composition and Molecular Design
At its core, abaloparatide is a synthetic 34-amino acid peptide analog. Its design is derived from the human parathyroid hormone-related promising PTHrP analogue isabaloparatide(known as BA058), a synthetic 34- residuepeptideanalogue of the human PTHrP residues that is currently in late Read more protein, specifically PTHrP(1-34). The primary objective in the development of this molecule was to create a stable, potent agent that effectively mimics the amino acid sequence of the first 34 residues of PTHrP.
The amino acid sequence is defined by a highly specific chain: Ala-Val-Ser-Glu-His-Gln-Leu Abaloparatide: A review of preclinical and clinical studies -Leu-His-Asp-Lys-Gly-Lys-Ser-Ile-Gln-Asp-Leu-Arg-Arg-Arg-Glu-Leu-Leu-Glu-Lys-Leu-Leu-Aib-Lys-Leu-His.
A notable feature of this amino-acid string is its homology. It possesses an amino acid sequence identical to that of PTH-related peptide in the first 20 amino acids, while incorporating strategic substitutions in the C-terminal region (positions 22–34) to optimize its stability and function. The inclusion of the non-proteinogenic amino acid 2-aminoisobutyric acid (Aib) at position 29 is a critical design choice that distinguishes it from endogenous proteins.
Technical Specifications and Identity
For those conducting laboratory analysis, the following parameters are often referenced:
* Molecular Formula: C174H300N56O49
* Molecular Weight: Approximately 3960.59 Da
* Classification: It is a parathyroid hormone-related protein (PTHrP) analogue medication concept used in research to study bone-related signaling pathways.
* Synthesis Strategy: The peptide is typically produced using the Solid Phase Peptide Synthesis (SPPS) method, which allows for the high-fidelity assembly of these 34 residues.
Why the Sequence Matters
In the world of biochemistry, the sequence is everything. By modifying the C-terminal region of the native PTHrP molecule, researchers have created an amino acid peptide that interacts selectively with the PTH1 receptor. This specificity is why the abaloparatide structure is so frequently cited in comparative studies against other analogs like teriparatide.
The Synthetic human PTH-related peptide analog containing 34 amino acids serves as a benchmark for how subtle changes in a protein chain can influence binding affinity and metabolic stability. When evaluating these materials for research, always ensure you are sourcing from providers that offer high-purity, standardized abaloparatide sequences verified by mass spectrom Abaloparatide (ABL) is a peptide designed withamino acid sequence identical to that of PTH-related peptide in the first 20 amino acids, with strategic Read more etry and HPLC.
Personal Perspective on Research Utility
In my own experience reviewing various research materials, the precision required to synthesize this 34-residue chain is impressive. The abaloparatide molecule represents a masterful application of structure-activity relationship (SAR) studies. Because the amino acid sequence is so closely guarded and calculated, researche Abaloparatideis an analog of human parathyroid hormone relatedpeptide,. PTHrP(1-34). It has 41% homology to hPTH(1-34) (human parathyroid hormone 1-34) and 76 Read more rs must be diligent in verifying that the peptide received matches the expected PTHrP(1-34)-based profile.
For those diving into the literature, keep in mind that the sequence is not just a list of letters; it is a functional map. Whether you are analyzing its folding patterns or its interaction with receptor sites, the structural integrity of the amino acid chain is the foundation of your entire experiment. Always verify the sequence against the Abaloparatide: A review of preclinical and clinical studies established CAS registry (247062-33-5) to ensure your data remains consistent with global research by MB Brent·2021·Cited by 61—Sequencedifferences ofabaloparatideare shown in bold and underlined. The amino acid X at position 29 is the non-proteinogenic amino acid 2- Read more standards.